Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Trexquant Investment LP

Trexquant Investment LP cut its holdings in Xencor, Inc. (NASDAQ:XNCR) by 59.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,241 shares of the biopharmaceutical company’s stock after selling 122,781 shares during the quarter. Trexquant Investment LP owned 0.12% of Xencor worth $1,913,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares in the last quarter. KBC Group NV increased its stake in shares of Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,337 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in Xencor in the 3rd quarter valued at about $205,000. Finally, Mutual of America Capital Management LLC purchased a new position in Xencor in the 4th quarter valued at about $244,000.

Xencor Stock Down 8.4 %

Shares of XNCR opened at $7.67 on Wednesday. Xencor, Inc. has a 52-week low of $7.60 and a 52-week high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $13.84 and a two-hundred day simple moving average of $19.41. The company has a market capitalization of $540.44 million, a PE ratio of -2.40 and a beta of 0.90.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. As a group, equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.